Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • Kansas
  • Overland Park


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Placebo Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
    NCT04040816
    Conditions:   Gout;   Hyperuricemia
    Intervention:   Drug: SAP-001
    Sponsor:   Shanton Pharma Co., Ltd.
    Recruiting
  • Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
    NCT03737981
    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
    NCT03709082
    Conditions:   HER2-positive Breast Cancer;   Breast Cancer Metastatic
    Interventions:   Drug: Palbociclib 75mg;   Drug: Letrozole 2.5mg;   Drug: T-DM1;   Drug: Palbociclib 100mg;   Drug: Palbociclib 125mg;   Drug: Palbociclib
    Sponsors:   University of Kansas Medical Center;   Pfizer
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
    NCT03418961
    Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
    NCT03304639
    Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
    Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
    NCT03971474
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    NCT02834013
    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
    NCT02775851
    Condition:   Desmoplastic Melanoma
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    NCT02761057
    Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
    NCT02004275
    Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
    NCT02972840
    Condition:   Lymphoma, Mantle Cell
    Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
    Sponsor:   Acerta Pharma BV
    Recruiting
  • Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
    NCT03238495
    Condition:   HER2-positive Breast Cancer
    Interventions:   Drug: Taxotere, Carboplatin, Herceptin + Pertuzumab;   Drug: Metformin
    Sponsor:   Qamar Khan
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Collecting Orthopedic Safety and Performance Data Using Surgeons Clinical Outcomes Registry (SCOR)
    NCT04032444
    Condition:   Orthopedics
    Intervention:  
    Sponsor:   Tornier, Inc.
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
    NCT03971071
    Condition:   Migraine Headache
    Interventions:   Drug: Erenumab 70 mg;   Drug: Erenumab 140mg;   Drug: Placebo
    Sponsor:   Amgen
    Recruiting
  • Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
    NCT02393794
    Conditions:   Triple-Negative Breast Cancer;   Breast Cancer
    Interventions:   Drug: Romidepsin;   Drug: Cisplatin;   Drug: Nivolumab
    Sponsors:   Priyanka Sharma;   Celgene Corporation;   Bristol-Myers Squibb
    Recruiting
  • CLUSTER Trial for Outbreak Detection and Response
    NCT04053075
    Condition:   Cluster Detection
    Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
    Recruiting
  • Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502
    NCT03609021
    Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
    Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Algovita Spinal Cord Stimulation System Hi-Fi Study
    NCT03622866
    Condition:   Chronic Pain
    Interventions:   Device: Ultra-high pulse width stimulation;   Device: Traditional pulse width stimulation
    Sponsors:   Nuvectra;   Bright Research Partners
    Recruiting
  • Palbociclib After CDK and Endocrine Therapy (PACE)
    NCT03147287
    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Palbociclib;   Drug: Fulvestrant;   Drug: Avelumab
    Sponsors:   Dana-Farber Cancer Institute;   Pfizer
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
    NCT03633396
    Condition:   Palmoplantar Pustulosis
    Interventions:   Biological: ANB019;   Drug: Placebo
    Sponsor:   AnaptysBio, Inc.
    Recruiting
  • A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
    NCT04015518
    Condition:   Palmoplantar Pustulosis (PPP)
    Interventions:   Drug: Spesolimab;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors
    NCT03996265
    Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Cancer Fatigue;   Cancer Survivor;   Complete Remission;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
    Interventions:   Drug: Bupropion Hydrochloride Controlled-release;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Gary Morrow;   National Cancer Institute (NCI)
    Recruiting
  • Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
    NCT03984448
    Conditions:   Diffuse Large B-Cell Lymphoma;   Double-Expressor Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
    NCT03983980
    Condition:   Plaque Psoriasis
    Interventions:   Drug: Tapinarof (DMVT-505);   Drug: Vehicle Cream
    Sponsors:   Dermavant Sciences GmbH;   IQVIA Biotech
    Recruiting
  • De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
    NCT03952585
    Conditions:   Basaloid Squamous Cell Carcinoma;   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Oropharyngeal Squamous Cell Carcinoma;   Papillary Squamous Cell Carcinoma;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Image Guided Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)
    NCT03933215
    Condition:   Multiple Sclerosis
    Intervention:   Drug: Cladribine Tablets
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)
    NCT03933202
    Condition:   Multiple Sclerosis
    Intervention:   Drug: Cladribine Tablets
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
    NCT03895372
    Condition:   Psoriasis
    Interventions:   Drug: PF-06826647 or Placebo;   Drug: PF-06826647
    Sponsor:   Pfizer
    Recruiting
  • Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors
    NCT03887702
    Conditions:   Hepatitis B Virus Positive;   Malignant Solid Neoplasm
    Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Drug: Tenofovir Alafenamide
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema
    NCT03866473
    Condition:   Diabetic Macular Edema
    Interventions:   Device: Retilux;   Device: Sham Light Device
    Sponsors:   Jaeb Center for Health Research;   National Institutes of Health (NIH);   National Eye Institute (NEI);   Juvenile Diabetes Research Foundation;   PhotoOptx LLC
    Recruiting
  • DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
    NCT03825315
    Condition:   Plantar Fasciitis
    Interventions:   Biological: DAXI for Injection: LOW Dose;   Other: DAXI for Injection: HIGH Dose;   Other: Placebo
    Sponsor:   Revance Therapeutics, Inc.
    Recruiting
  • Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
    NCT03821402
    Condition:   Upper Limb Spasticity
    Interventions:   Biological: DAXI for injection dose LOW DOSE;   Biological: DAXI for injection dose MEDIUM DOSE;   Biological: DAXI for injection Dose HIGH DOSE;   Other: Placebo
    Sponsor:   Revance Therapeutics, Inc.
    Recruiting
  • A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
    NCT03816163
    Conditions:   Pancreatic Cancer;   Metastatic Pancreatic Cancer;   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Drug: zolbetuximab;   Drug: nab-paclitaxel;   Drug: gemcitabine
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
    NCT03811002
    Conditions:   Limited Stage Lung Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
    NCT03809663
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Tezepelumab;   Other: Placebo
    Sponsors:   Amgen;   AstraZeneca
    Recruiting
  • Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer
    NCT03801902
    Conditions:   Lung Non-Small Cell Carcinoma;   PD-L1 Overexpression;   Recurrent Lung Carcinoma;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Radiation: Fractionated Stereotactic Radiation Therapy;   Radiation: Hypofractionated Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
    NCT03793166
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • The SNAP Trial: SPRINT® Peripheral Nerve Stimulation for the Treatment of Neuropathic Post-Amputation Pain
    NCT03783689
    Conditions:   Neuropathic Pain;   Amputation
    Intervention:   Device: SPRINT Peripheral Nerve Stimulation (PNS) System
    Sponsor:   SPR Therapeutics, Inc.
    Recruiting
  • Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
    NCT03778931
    Condition:   Breast Cancer
    Interventions:   Drug: Elacestrant;   Drug: Standard of Care
    Sponsor:   Radius Pharmaceuticals, Inc.
    Recruiting
  • An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
    NCT03777436
    Condition:   Psoriasis
    Interventions:   Drug: Apremilast;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
    NCT03777059
    Condition:   Episodic Migraine
    Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
    Sponsor:   Allergan
    Recruiting
  • Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
    NCT03757949
    Condition:   Bladder Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Dietary Supplement: Nutritional Intervention;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
    NCT03738423
    Condition:   Atopic Dermatitis
    Interventions:   Drug: REGN3500;   Drug: REGN3500-Matching Placebo
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
    NCT03723928
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
    Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
    NCT03712605
    Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
    NCT03701282
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
    NCT03683030
    Condition:   Atrial Fibrillation
    Intervention:   Device: Radiofrequency Ablation
    Sponsor:   Biosense Webster, Inc.
    Recruiting
  • Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
    NCT03678025
    Conditions:   Castration Levels of Testosterone;   Metastatic Prostatic Adenocarcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Drug: Abiraterone;   Drug: Bicalutamide;   Drug: Degarelix;   Drug: Docetaxel;   Drug: Flutamide;   Drug: Goserelin Acetate;   Drug: Histrelin Acetate;   Drug: Leuprolide Acetate;   Drug: Nilutamide;   Procedure: Orchiectomy;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Radical Prostatectomy;   Drug: Triptorelin
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Effects of Pneumatic Vitreolysis on Macular Hole
    NCT03677869
    Conditions:   Vitreomacular Traction (VMT);   and Full-thickness Macular Holes (MH)
    Intervention:   Device: Intraocular gas (C3F8)
    Sponsors:   Jaeb Center for Health Research;   National Institutes of Health (NIH);   National Eye Institute (NEI)
    Recruiting
  • National Cardiogenic Shock Initiative
    NCT03677180
    Conditions:   Cardiogenic Shock;   Acute Myocardial Infarction;   STEMI - ST Elevation Myocardial Infarction;   NSTEMI - Non-ST Segment Elevation MI;   Heart Attack
    Intervention:  
    Sponsors:   Henry Ford Health System;   Abiomed Inc.;   Chiesi Farmaceutici S.p.A.
    Recruiting
  • Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
    NCT03654768
    Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
    NCT03650114
    Condition:   Relapsing Multiple Sclerosis
    Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Effects of Pneumatic Vitreolysis on Vitreomacular Traction
    NCT03647267
    Condition:   Vitreomacular Traction
    Interventions:   Device: Pneumatic Vitreolysis (C3F8 injection);   Other: Observation
    Sponsors:   Jaeb Center for Health Research;   National Institutes of Health (NIH);   National Eye Institute (NEI)
    Recruiting
  • Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT. NODE-302
    NCT03635996
    Condition:   Paroxysmal Supraventricular Tachycardia
    Intervention:   Drug: Etripamil NS 70 mg
    Sponsors:   Milestone Pharmaceuticals Inc.;   Medpace, Inc.
    Recruiting
  • Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
    NCT03617367
    Condition:   Cervical Dystonia
    Intervention:   Biological: daxibotulinumtoxinA for injection
    Sponsors:   Revance Therapeutics, Inc.;   Syneos Health
    Recruiting
  • Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
    NCT03608397
    Condition:   Cervical Dystonia
    Interventions:   Biological: DaxibotulinumtoxinA for injection;   Biological: Placebo
    Sponsors:   Revance Therapeutics, Inc.;   Syneos Health
    Recruiting
  • SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
    NCT03607838
    Condition:   Lumbar Disc Herniation
    Interventions:   Drug: SI-6603;   Drug: Sham injection
    Sponsor:   Seikagaku Corporation
    Recruiting
  • A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
    NCT03598790
    Conditions:   Chronic Plaque Psoriasis;   Moderate to Severe Chronic Plaque Psoriasis
    Intervention:   Drug: Bimekizumab
    Sponsor:   UCB Biopharma S.P.R.L.
    Recruiting
  • Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
    NCT03598257
    Condition:   Inflammatory Breast Carcinoma
    Interventions:   Drug: Olaparib;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Comparison of the Effects of Two Spinal Cord Stimulation (SCS) Therapies on Subject Reported Pain (BENEFIT-02)
    NCT03594266
    Conditions:   Chronic Low Back Pain;   Chronic Leg Pain
    Interventions:   Device: Therapy A Spinal Cord Stimulation Parameter Set;   Device: Therapy B Spinal Cord Stimulation Parameter Set
    Sponsor:   Biotronik, Inc.
    Recruiting
  • Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
    NCT03587805
    Condition:   Atopic Dermatitis
    Intervention:   Drug: Tralokinumab
    Sponsor:   LEO Pharma
    Recruiting
  • Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
    NCT03578081
    Condition:   Malignant Neoplasm
    Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
    NCT03574597
    Conditions:   Overweight;   Obesity
    Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
    NCT03488693
    Condition:   Breast Cancer
    Interventions:   Radiation: Radiation;   Other: No Radiation
    Sponsors:   Canadian Cancer Trials Group;   Alliance for Clinical Trials in Oncology;   Eastern Cooperative Oncology Group;   NRG Oncology;   Southwest Oncology Group
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
    NCT03464019
    Condition:   Paroxysmal Supraventricular Tachycardia
    Interventions:   Drug: Etripamil;   Drug: Placebo;   Device: Aptar Pharma Nasal Spray
    Sponsors:   Milestone Pharmaceuticals Inc.;   Medpace, Inc.
    Recruiting
  • Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
    NCT03409107
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat (GSK1278863);   Drug: Placebo;   Drug: Iron therapy
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
    NCT03373045
    Condition:   Asthma
    Intervention:  
    Sponsors:   AstraZeneca;   Parexel;   MedImmune LLC
    Recruiting
  • Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
    NCT03372161
    Condition:   Lumbosacral Radicular Pain
    Interventions:   Drug: SP-102;   Drug: Placebo
    Sponsors:   Semnur Pharmaceuticals, Inc.;   Worldwide Clinical Trials;   Scilex Pharmaceuticals, Inc.
    Recruiting
  • BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
    NCT03371719
    Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
    Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
    NCT03367702
    Condition:   Stage II Prostate Adenocarcinoma
    Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
    NCT03268954
    Conditions:   Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
    Interventions:   Drug: Azacitidine;   Drug: Pevonedistat
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
    NCT03258554
    Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group;   NRG Oncology
    Recruiting
  • MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
    NCT03217266
    Condition:   Soft Tissue Sarcoma
    Interventions:   Drug: MDM2 Inhibitor AMG-232;   Radiation: Radiation Therapy
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
    NCT03199885
    Conditions:   Breast Adenocarcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Biological: Pertuzumab;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
    NCT03180268
    Conditions:   Grade II Meningioma;   Intracranial Meningioma
    Interventions:   Other: Clinical Observation;   Radiation: Radiation Therapy
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
    NCT03137771
    Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT);   Drug: Docetaxel;   Drug: Gemcitabine;   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Drug: Pemetrexed Disodium;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: Erlotinib Hydrochloride;   Drug: Pembrolizumab
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
    NCT03070886
    Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
    Interventions:   Drug: Bicalutamide;   Drug: Docetaxel;   Radiation: External Beam Radiation Therapy;   Drug: Flutamide;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Leuprolide Acetate;   Drug: Nilutamide
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
    NCT03055013
    Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
    Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
    NCT03044249
    Conditions:   Psychosis;   Dementia;   Aggression;   Agitation;   Alzheimer Dementia
    Interventions:   Drug: MP-101;   Drug: Placebo
    Sponsor:   Mediti Pharma Inc.
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
    NCT03028350
    Condition:   Asthma, Aspirin-Induced
    Interventions:   Drug: Ifetroban Oral Capsule;   Drug: Placebo Oral Capsule
    Sponsor:   Cumberland Pharmaceuticals
    Recruiting
  • Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
    NCT02928497
    Condition:   Stroke
    Interventions:   Device: WATCHMAN LAAC Device Implant;   Drug: Single Antiplatelet Therapy or No Therapy (Control)
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
    NCT02923726
    Condition:   Sudden Cardiac Death
    Interventions:   Device: Arm 1 (ATP+Shock);   Device: Arm 2 (shock only)
    Sponsors:   Boston Scientific Corporation;   ICON plc
    Recruiting
  • S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
    NCT02728596
    Conditions:   Febrile Neutropenia;   Stage 0 Breast Cancer;   Stage 0 Colorectal Cancer;   Stage 0 Non-Small Cell Lung Cancer;   Stage I Colorectal Cancer;   Stage IA Breast Cancer;   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Breast Cancer;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Colorectal Cancer;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Breast Cancer;   Stage IIB Colorectal Cancer;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIC Colorectal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
    Interventions:   Other: Preventive Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Patient-Centered Outcomes Research Institute
    Recruiting
  • Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
    NCT02635009
    Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Capecitabine in Metastatic Breast and GI Cancers
    NCT02595320
    Conditions:   Breast Cancer;   Gastrointestinal Cancer
    Intervention:   Drug: Capecitabine
    Sponsor:   Qamar Khan
    Recruiting
  • aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation
    NCT02513797
    Condition:   Atrial Fibrillation
    Interventions:   Device: LARIAT + PVI;   Device: Pulmonary Vein Isolation
    Sponsor:   AtriCure, Inc.
    Recruiting
  • Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
    NCT02507687
    Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
    Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
    Sponsor:   Allergan
    Recruiting
  • Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
    NCT02466971
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
    NCT02179086
    Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
    Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: photon beam radiation therapy;   Radiation: proton beam radiation therapy;   Drug: temozolomide;   Other: laboratory biomarker analysis
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Dimethyl Fumarate (DMF) Observational Study
    NCT02047097
    Condition:   Multiple Sclerosis
    Intervention:   Drug: dimethyl fumarate
    Sponsor:   Biogen
    Recruiting
  • Integrated Cancer Repository for Cancer Research
    NCT02012699
    Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breast Cancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer;   Neuroendocrine Tumors;   Plasma Cell Dyscrasia;   Healthy Control
    Intervention:  
    Sponsor:   University of Nebraska
    Recruiting
  • Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    NCT01872975
    Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis
    NCT04178967
    Condition:   Atopic Dermatitis
    Interventions:   Biological: Lebrikizumab;   Other: Placebo
    Sponsor:   Dermira, Inc.
    Recruiting
  • Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
    NCT03907488
    Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
    NCT03769090
    Condition:   Asthma
    Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
    Sponsor:   Bond Avillion 2 Development LP
    Recruiting
  • Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
    NCT03627767
    Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
    NCT03580369
    Condition:   Chronic Spontaneous Urticaria
    Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
    NCT03568318
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib;   Drug: Topical corticosteroids (TCS)
    Sponsor:   AbbVie
    Recruiting
  • Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
    NCT03428646
    Condition:   Dermatitis, Atopic
    Intervention:   Drug: Dupilumab
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
    NCT03052517
    Condition:   Asthma
    Interventions:   Drug: QAW039 Dose 1;   Drug: QAW039 Dose 2;   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
    NCT01442194
    Condition:   Multiple Sclerosis
    Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC